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Expression of vascular permeability factor/vascular 
endothelial growth factor (VPF/VEGF) is markedly 
increased in the epidermis of lesional psoriatic skin 
and in healing skin wounds. In this study, we char-
acterized the effects of several cytokines and growth 
factors on the expression and secretion ofVPF/VEGF 
mRNA and protein by cultured human epidermal 
keratinocytes, as well as the effect of VPF/VEGF on 
the growth of cultured human dermal microvascular 
endothelial cells. Transforming growth factor-a, epi-
dermal growth factor, and phorbol myristate acetate 
markedly stimulated VPFIVEGF mRNA expression 
by cultured keratinocytes; as in psoriatic skin, the 
three most common VPF/VEGF isoforms (encoding 
proteins of 121, 165, and 189 amino acids) were 
upregulated to an equal extent. Transforming growth 
factor (TGF)-a, epidermal growth factor, and phor-
bol myristate acetate also enhanced the secretion of 
VPF/VEGF by keratinocytes; in contrast, a number of 
V ascular perm eabili ty fac to r (VPF) w as originally described as a cytokin e present in tumor-cell- con-ditioned m edium that was presumed to acco unt for the w e ll kn own hyp erpermeability of tumor mi-crovessels to plasm a proteins and other circul ating 
m acromolecules [1 ]. T he abundance o f VVF and th e kinetics of its 
appea ran ce in tumor ascites sugges ted that VVF might contribute 
impo rtantly to m alignant ascites fluid accumulation [2-4]. Subse-
quent purification revealed that VPF is a homodime ric glycoprotein 
that enhances microvasculat· permeabili ty wi th a potency, on a 
m olar basis , so me 50,000 times higher than that of histamine [5] . 
More recently, a number o f groups have isolated and purifi ed an 
endothe lial cell growth factor that is secreted by various cell types 
in cluding U 93 7 cells, normal pituitary folli cular cells, and rat 
glioma cells [6-1 2] . T his facto r was mi togeni c for endo thelial cells 
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Abbrev iatio ns: K OM , kcratinocytc basal mcditm1; KG M, kcratinocyte 
growth medium; (rh)VPF/VEGF, (recombinant human) vascular perme-
abi lity factor/ vascular endothe li al growth factor. 
other cytokines including interleukin (IL)-1, IL-6, 
IL-8, tumor necrosis factor-a, interferon-y, and 
transforming growth factor-{3 did not induce VPF/ 
VEGF secretion. The VPFIVEGF secreted by kerati-
nocytes was biologically active in that, like recombi-
nant human VPFIVEGF, it potently stimulated 
dermal endothelial cell proliferation. Scatchard anal-
ysis revealed two high-affinity VPF/VEGF binding 
sites on dermal endothelial cells with dissociation 
constants of 51 pM and 2.9 pM. These results suggest 
that the avascular epidermis has the capacity to 
regulate dermal angiogenesis and microvascular per-
meability by a paracrine mechanism involving the 
secretion of VPFIVEGF. Similar mechanisms may b e 
anticipated in a variety of inflammatory and neoplas-
tic skin diseases characterized by microvascular hy-
perpermeability, edema, and angiogenesis. J l1west 
Dermatol 105:44-50, 1995 
i11 tlitt·o [7-1 0,13] and induced an giogenesis i11 11ivo [7,11] ; the refore, 
it was ca lled vascular endothelial growth fac to r (VEGF). H o w ever, 
protein and eDNA sequencing revealed that VPF <md VEGF arc 
products of the sam e gene [11 , 13), and the names VPF and VEGF 
hav e been used synonymously. R ecently , tw o transmembrane type 
III tyrosine kinases, KDR [14] and ftt- 1 (1 5), have been identified 
as high-afl:inity VPF/ VEGF receptors. 
T he VPF/ VEGF fiunily includes several peptides that arise from 
altemative splicing of a single gene [1 6,17). T ransfection experi-
m ents using C hinese hamster ova ry cells sho w ed that the 121 and 
165 ami.no acid peptides, VPF/VEGF 12 1 and VPF/ VEGF 1r,5 , arc 
soluble, whe reas t\vo larger isofo rms, VPF/VEGF 1 ~o~~ and VPF/ 
VEGF _06 , rem ain cell associated [1 8] ; howe ver, all VPF/ VEGF 
species arc reported to have equivalent biologic activity with 
respect to increasing microvascular permeability and enhancing 
endothelial cell division [17). 
Recently, w e reported enhanced eJ.-prcssion of VPF/VEGF 
mRNA in the e pidermis o f healing ski.n wounds in guinea pigs and 
rats [19) and increased expression of VPF/ VEGF and its two 
receptors, flt-1 and KDR, in lesio nal psoriatic skin (20) , both 
conditi ons that are chara cterized by mi crovascular h yperperm cabil-
ity and angiogenesis [1 9,2 1) . T hese findin gs suggested that VPF/ 
VEGF might play an import<mt regulato ry role in the patho physi-
ology o f the cutaneous mi crovasculature. . 
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ln the present study , we tested the capacity of cytokin es and 
growth factors that have been associated with the pathogenesis of 
wound healing and/or with psoriasis for their ability to regulate the 
expression ofVPF/VEGF mRNA express ion and protein secretion 
in cul ture d epid e m1al keratinocytes. Moreover, we characterized 
the mitogenic e ffect of re combinant human Vllf/VEGF (rhVPF/ 
VEGF) as well as of VPF/VEGF present in keratinocyte-condi-
tione d m e dia on culture d human dermal microvascular e n dothe lia l 
cells (HDMEC), and m easure d the binding pro p e rties of rhVPF/ 
VEGF to HDMEC. These investigations revealed induction of 
VPF/VEGF mRNA expression and prote in secretion after iu 1itro 
stimulation of keratinocytes with transforming growth factor 
(TGF)-a, e pidermal growth factor (EGF), and phorbol myristate 
acetate (PMA). More over, the sam e three mRNA isoforms were 
induced that are expressed in p soriatic skin lesio n s. Finally, VPF/ 
VEGF exerte d a pote nt and selective mitogenic e ffect on HDMEC, 
inte racting with two hig h-affinity rece ptors. 
MATERIALS AND MET HODS 
Reagents Recombinant human interl eukin-1/3 (IL-l J3), IL-6, IL-8, mac-
rophage-chemotactic protein-1 (MC P-1) , interferon-gamma (IFN-y) , and 
TGF-a were obtained from British Biotechnology (Abingdon, UK), recom-
binant human EGF from C lone tics (San Diego, CA), and recombinant 
human TGF-13 from Collaborative Biomedical Products (Bedford, MA). 
R ecombinant human tumor necrosis factor- alpha (TNF-a ) was kindl y 
provided by BASF-Knoll (Mannheim, Germany). Recombinant human 
VPF/VEGF was prepared by one of us (SL). The affinity-purified rabbit 
polyclonal antibody 618 against human VPF/ VEGF was kindly provided by 
Dr. Donald R. Senger. PMA and bovine serum albumin were obtained from 
Sigma (St. Louis, MO) . [32P]-dCTP, l32P]-UT P, and [methyl-3H]-thymi-
dine (82.4 C i/ mmol) were o btained from DuPont NEN (Boston, MA) . 
1251-VPF/ VEGF (NEX 328) was a kind 1,rift of Diane True, D uPont N EN. 
Cell Culture Human epidermal keratinocytes were isolated from neona-
tal foreskin s and propagated in serum-free keratinocyte growth medium 
(K.GM; C lonetics) as described previously [22]. For all experiments, kera-
tinocytes were used at passage 2 to 4. HDMEC were isolated from neonatal 
foreski.ns as described previously [23]. HDMEC were grown on fibronectin-
coated dishes in endothelial cell basa l medium (EBM ; C lonetics) \vi th 20% 
fetal bovine serum (Gibco BRL, Grand Island, NY) , 50 mM dibutyryl cyclic 
adenosine monophosphate, 1 p,g/ ml hydrocortisone acetate, and antibiotics 
(Sigma) , and were used at passage 3 to 6. Human dermal fibroblasts, derived 
from neonatal foreskins and cultured in Dulbecco's modified Eagle's 
m ediwn containing 10% fetal bovine serum and antibiotics, were used at 
passage 4 to 6. 
Immunofluorometric Assay for VPF/VEGF in Conditioned Media 
Confluent epidermal keratinocyte cultures in 24-wcU plates were incubated 
in 1 m l serum-free keratinocytc basal medjum (KBM) either with or 
without fL-1.-J3 , EGF, TGF-a, TGF-J3, PMA (all 10 ng/ml), IL- 2, JL-6 , 
IL-8, MCP-1 , IFN -y, or TNF-a (all 100 ng/ml) for 48 h. In additional 
experiments, keratinocyte cultures were i11cubatcd with graded doses of 
EGF (0.1-100 ng/ml) either alone or in combina tion with 100 ng/ ml 
TGF-a for 48 h . Also, keratinocytc cultures were incubated in KBM or in 
complete keratinocyte growth medium (KGM) for up to 5 d. Conditioned 
medja were harvested , clarified by centrifugation, and stored frozen at 
-80°C. VPF/VEGF was quantified by a two-site, time-resolved immu-
nofluoromctric assay as described [20,24]. Tlus assay specifically detects aU 
known fo rms of VPF/VEGF with a sensitiv ity of approximately 5 pM ; it 
docs not cross react with basic fibroblast growth factor or platele t-derived 
growth fac tor. Data arc expressed as pM VPF/ VEGF per 1 X 106 
keratinocytes . In these and other experiments, statistical significance w as 
calculated with the Dunnett multiple comparison test . 
lr1 Situ Hybridization Confluent keratinocytc cultures grown in Lab-
Tek tissue culture chambers (Nunc, Naperville, IL) were incubated in KBM 
w ith or without 10 ng/ml EGF or 10 ng/ml TGF-a. After 24 h , ccUs were 
fixed in 4% paraformaldehyde in phosphate-buffered saline , pH 7 .4, at 4 oc. 
and stored in 70% ethanol at 4°C fo r up to 2 weeks. Hybridization was 
performed with VPF/VEGF antisense or sense (control) riboprobcs as 
described previously [25,26]. 
Ribonuclease Protection Assay C011fluen t keratinocyte cultures in 
1 00-mm dishes were incubated for 24 h in KBM with or without 10 ng/ml 
TGF-a, 10 ng/ml EGF, or 10 ng/ ml PMA . Total cellular RNA was isolated 
from cultured kcratinocytes and from fibrosarcoma HT 1080 cell s (positive 
control) as described [20]. RNA was also ex tracted fro m 4-nun punch 
KERATINOCYTE-DERIVED VPF/VEGF 45 
biopsies obtajned from the lesional skin of three patients with untreated 
acute guttare psoriasis. Biopsies were homogenized in 4 M guanidine-
isotlu ocyanatc conta.ining 100 p,M 2-mercaptoethanol , and total cellular 
I~NA was separated by ultraccntrifi.1gation through a 5.7 M cesium chloride 
cusluon acco rding to standa rd protocols [27]. A single- stranded 420 base 
pair (bp) anti sense VPF/ VEGF riboprobe was prepared by i11 virro transcrip-
tion of a 377-bp human VPF/ VEGF16? eDNA fragment, usin g the Ribo-
probe 11 kit (Promcga) in the presence of [cx-32P]UTP. Samples of RNA (5 
p,g each) were hybridized with 32P- Iabcled VPF/VEGF riboprobc and 
digested with R.Nase using the RPA Il Kit {Ambion, Austin, TX) accorrling 
to the manufacturer's protocol. As control s, 1 0-fLg aliquots of yeast RNA 
were hybridized with the same am ount of labeled VPF/VEGF riboprobc, 
witl1 or without addition of RNase. H ybridization products were scpa.ratcd 
on a 6% polyacrylan1idc-8 M urea gel. RNA Century Marker Template 
(Ambion) was used to generate tra nscripts of known size, wluch served as 
molecular weight markers. T he expected sizes of the protected bands were 
377 nt for VPF/VEGF 189, 276 and 29 n t fo r VPF/ VEGF",5 , and 144 and 29 
n t for VPF/VEGF121. An addi tio nal band, approximately 347 nt in size, was 
present onl y in samples that con tained the 377-nt band and most probably 
arose by partial RNase digestion of an AU-rich region of the 377-bp hybrid, 
exactly 30 nuclcotides from one end of the protected fragment. 
Cell Proliferation Assays HDMEC were seeded at 5 X 103 cells/cm2 
into 24-well tissue culture clusters . T he fo llowing day, culrures were 
incubated in endothelial basa l medium (EBM) witl1 2% fetal bovine serum, 
with or without rhVPF/VEG F (<l.Ol-1 00 ng/ ml). Fresh medium contall.ung 
VPF/VEGF was added 2 d later. Two days later, triplicate cultures were 
trypsinized and cell coun ted. For determination of ·' H-thymidinc incorpo-
ration, quadrupli cate cultures were incubated for 6 h at 37°C with 1 p,Ci/ ml 
-' H-thymidine, and incorporated radioactivity was detem1incd as described 
[28,29]. Epidermal keratinocytes and dermal fibrobla sts were treated iden-
tically in their respective growth medja (see above) . 
In additional experiments, triplicate HDMEC cultures were incubated for 
-1 d in EB M with 2% fetal bovine serum supplemented witl1 kcratinocytc-
conditioned KGM (1-20'%, v/v), or, as a control. with tl1e same amounts of 
KGM. Keratinocytc-conditioned medium was . collected fro m conflu en t 
kc ra tinocytc cultures that had been incubated in 1 00-mm djshcs fo r 48 h in 
5 ml KGM conrai1ung 10 ng/ ml EGF. -'H-th)~1lidine incorporation was 
dete rmined as described above. 
1251-VPF/VEGF Binding to HDMEC HDMEC were grown to conflu-
CJ1ce in six-well plates (2 X 105 ceJJs/ welJ) . The cells were washed twice 
with cold binding buffer (DME/ F12 medium contai1u ng 20 mM HEPES and 
0 .2% ge la tin). O ne nullili tcr of binding buffer containing recombinant 
human 1251-VPF/ VEGF (12 pg/ml to 9 ng/ ml) was tl1en added to each well. 
Binding of 1251-rhVPF/ VEGF to HDMEC was allowed to proceed on a 
rotating platform fo r 4 h at 4 °C . T he supernatant was removed and 
radioactivity assessed to dctcnninc free co un ts per well. After two washes 
with icc-cold binding buffe r, 1 ml of lysis buffer (binding buffe r containing 
5% T ri ton X-100 and 1% sodium dodccylsul f.1tc) was added to each well , 
and lysis was aJlowed to proceed at 4°C for 30 min with vigoro us circu lar 
agitation. T he solubilized cell lysate was counted in a WaUac LKB Wizard 
1470-5 gamma counte r to de termine the amount of bound 125 1-rhVPF/ 
VEGF per well . Non-specific binding w as detem1incd in tl1e presence of90 
ng/ ml (i.e ., at least a one hundredfold excess) unlabeled rhVPF/ VEGF 
(PcproTech, Rocky Hill, NJ). Each determination was performed in 
duplicate. Specific binding was determined by subtracting non-specific 
binding fro m the tota l binding. Scatchard analysis (30] was performed ,.vith 
the aid of the KELL sui te of radiol.ig:md binding programs (Biosoft, 
Ferguson, MO) adapted by McPherson (3 1] fro m the LIGAND program of 
Munson and R.odbard [32]. T he dissociation constant and receptor numbers 
were ca lculated using a va lue of 45 kD for the mass of tl1e VPF/VEGF 
dimer. 
RESULTS 
Regulation of VPF/VEGF Synthesis aud Secretion in Cul-
tured Epidermal Keratinocytes To evaluate the regulation of 
VPF/VEGF produ ction by epide m1al keratinocytes, confl u en t cul-
tures were incubated e it h e r in serum-free KBM or in complete 
KGM for up to 5 d. C ulture supematants were th e n immunoassayed 
for the presence of VPF/VEGF protein . Keratinocyte cul tures 
inc ubated in complete KGM secreted signifi cant amow1ts ofVPF/ 
VEGF th at fi rst became detectable after 24 h of c ulture (Fig 1A) 
and reached a m aximum of 150 pM VPF/ VEGF p er well at 5 d. 
Kcratinocytes incubate d in unsupplemented KBM released substru1-
tially smaller amounts of VPF/ VEGF, up to only 60 pM , into the 
culture m e dium . 
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To identify the factor(s) responsible for increased VPF/VEGF 
production when keratinocytes were cultured in KGM, several of 
the supplements present in KGM were tested individually for their 
ability to induce VPF/VEGF secretion by epidermal keratinocytes 
cultured in KBM. O ne likely cand idate was EGF that is present in 
KGM at a concentration of 10 ng/ml. As shown in Fig 1B, EGF 
enhanced the secretion of VPF/VEGF by epidermal keratinocytes 
in a dose-dependent fashion; the minimal etfective concen trati on 
was 3 ng/ml and levels as high as 11.0 pM/106 cells were achieved 
with 100 ng/ml EGF. 
Because we recently dem o nstrated increased express ion of VPF/ 
VEGF in the epidermis of lesional psoriatic skin [20] and healing 
skin wounds [19) , w e investigated whether other cytokines or 
g rowth facto rs that have been associated with these conditions 
might also lead to increased syn thesis and/or secretion of VPF/ 
VEGF in cultured keratinocytes. N o significant increase of VPF/ 
VEGF was detected in keratinocyte-conditioned medium following 
48 h of culture with lL-1 , IL-6, IL-8, M CP-1, IFN--y, TNF-a, or 
TGF-13 (Fig 2). In contrast, a m arked increase of VPF/VEGF was 
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Figure 1. A, Detection of secreted VPF/VEGF in keratinocyte-
conditioned media by immunofluorontetric assay. Confluent kerati-
nocytc cultures were incubated for up to 5 d in keratinocytc basal medium 
(ICBM . 0 ) or in fi.11ly supplemented medium (KGM, e). Data arc expressed 
as pM VPF/VEGF per dish (mean ::+: SD, n = 3). p < 0.01 for 48-120 h. 
B, EGF dose-dependentl y enhances secretion of VPF/VEGF by kcra tino-
cytes. Confluent keratinocyte cul tures were incubated for 48 h in KBM with 
or without EGF. Data are expressed as pM VPF/ VEGF per l X 106 
keratinocytes (mean :±: SD; n = 3). 
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Figure 2. EGF, TGF-a, and PMA enhance secretion ofVPF/VEGF 
by keratinocytcs iu 11itra. Confluent keratinocyte cultures were incubated 
for 48 h in KBM supplemented with cytokines and growth fi1ctors in 
concentrations given in Materials a11d Methods . As a control, KBM was 
supplemented with bovine serum albumin (BSA) in the same protein 
concentration used for the cytokine preparations. There was significant 
increase of VPF/VEGF levels in condi tioned media by EGF, TGF-a . and 
PMA (p < 0.01). T he data presented were obtained fro m a single 
experiment representa tive of three that were performed with equivalent 
results. Data are expressed as pM VPF/VEGF per 1 X 1 O'' kera tinocytes 
(mean ± SD; n = 3). 
found in conditioned rnedium following culture with EGF or 
TGF-a [i. e., approximately sevenfold increase in cultures with 100 
ng/ ml TGF-a (Fig 2)]. At equivalent protein concentrations, 
TGF- a consistently induced greater secretio n of VPF/VEGF th<ul 
did EGF. T he tumor pro moter PMA also enhanced VPF/ VEGF 
secretion by up to sixfold above baseline values. 
To investigate whether the increased synthesis/ secretion of 
VPF/VEGF protein by growth factor-stimulated keratinocytes was 
due to enhanced expression ofVPF/VEGF mRNA, we performed 
it1 sitt1 hybridization on keratinocyte cultures grown as described in 
Materials and M ethods. Specific labeling for VPF/VEGF mRNA was 
detected in keratinocytes cultured for 48 h in KBM (Fig 3A); 
however , addition of either EGF or TGF- a markedly enhanced the 
expression ofVP·F/VEGF mRNA in a ll keratinocytes (Fig 3B, q . 
No specific labeling was seen with sense (control) probe (Fig 3D). 
T he VPF/VEGF fa m.ily includes at least four related p eptides that 
arise from alternative splicing of a single gene [1 6,17). We there-
fore investigated whether growth fac tor stimulation led to prefer-
ential induction of all or a subset of the difl:e rent VPF/VEGF 
isoforms. Using ribonuclease protection assays with a VPF/ 
VEGF18.;-derived riboprobe, w e were able to distinguish among 
the three most common VPF/VEGF splic ing variants, VPF/ 
VEGF 121, VPF/VEGF",5 , and VPF/VEGF 189 . Keratinocytes cul-
tured in b asal medium predominantly expressed mRNAs coding for 
VPF/VEGF121 and VPF/VEGF ., 65 and only to a lesser extent for 
VPF/VEGF189 . Incubation of keratinocytes with TGF-a, EGF, or 
PMA induced enh anced expression of the same three mR.N A 
isoforms and to approximately the sam~ extent (Fig 4) . We also 
performed ribonuclease protection assays o n RNAs' extracted from 
three acute psoriatic skin lesions (Fig 4). As was the case following 
gro wth factor stimulation of cultured keratinocytes, mRNAs en-
coding the 121, 165, and 189 VPF/VEGF isoform s were all stron gly 
expressed. 
Mitogenic Effect of rhVPF/VEGF and of Keratinocyte-
Conditioned Media on HDMEC VPF/ VEGF is known to 
stimulate the proliferation of several types of cultured endothelial 
cells but its etfects on HDMEC had not previously been tested. 
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F igure 3. Localization of VPF/VEGF mRNA in c ultured human 
epidermal keratinocytes by iu situ hybridization. Confluent keratino-
cyte cultures were incubated for 24 h either in KBM alone (A) or in KBM 
supplem ented with 10 ng/ml TGF-a (B) or 10 ng/ml EGF (C). VPF/ VEGF 
an tisense riboprobe labeling shows marked induction of VPF/ VEGF 
mRNA by TGF-a and EGF. Control hyb ridi zation of TGF-a- trcated 
culture with VPF/VEGF sense riboprobe demonstrates low level of back-
ground labeling (D). A-D, bnr, 25 p.m . 
rhVPF/VEGF induced a d ose- dep endent increase in both HDMEC 
cell number (Fig SA) and DNA synth esis (Fig SB); th e minimal 
effective concentration was 0.3-1.0 ng/ml. T h e mitogenic effect 
was selective for HDMEC in that rhVPF/VEGF did not stim ulate 
Keratinocytes Psoriasis 
+ C TGFa EGF PMA 2 3 
VPF189[ ill::: 
VPF1ss 276-
VPF121 144-
Figure 4. TGF-a, EGF, and PMA enhance VPF/VEGF mRNA 
expression b y epidermal keratinocytes. Ribonuclease protection assay 
of total RNA (5 p.g each) extracted fro m HT 1080 fibrosarcoma cells 
(positive control) and from confluent keratinocye cultures demonstrates 
induction of mLWAs for VPF/VEGF 12 1, VPF/VEGF 165 , and VPF/ 
VEGF 189 . A similm· patte rn of al ternative m.IWA splicing was o bserved in 
RNA extracted fro m the lcsional skin of three different patients with 
psoriasis . Note that altho ugh the bands in difi'eren t lanes differ i.n intensity, 
the relative levels of the di!lcrent isoforms arc approximately equal in all 
samples. Numbers in the left margin represent number of bases of the three 
different mlWA species. Yeast RNA control without ( - ) or with (+) 
R.Nasc digestion. 
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F ig ure 5. VPFIVEGF is a potent, selective mitogen for HDMEC. 
HDMEC were incubated with or witho ut rhVPF/ VEGF for 4 d in EBM · 
medium. A, Cell numbers (mean ::':: SD, n = 3). B, 3 H-thymidine 
incorporation (CPM, e). No effect ofrhVPF/ VEGF on the proliferation of 
epidermal keratinocytes ('f) or dermal fibrob lasts ('V). Bars, mean ::':: SD 
(n = 4). 
th e growth of epidermal keratinocytes or d ermal fibroblasts (Fig 
SB) . 
To determine w heth er th e immunoreactive VPF/VEGF present 
in keratinocyte-conditioned m edia h ad biologic activity, HDMEC 
were cul tured in EBM supplemented with 2% fetal bovine serum 
and with graded amou nts of conditioned m e dia harvested from 
keratinocytes cultured for 48 b in serum-free KGM . Addition of 
keratinocytc-conditioned media to HDMEC c ul tu res enhanced the 
incorporation of 3H-thymid.i.ne into DNA up to threefold and in a 
dose -dependent manner, as compared to addition of control KGM 
medium (Fig 6). Depletion of VPF/ VEGF by immunoadsorption 
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removed more than 80% of the mitogen.ic activity of keratinocyte-
conditioned media. Thus, the immunoreactive V11 F/VEGF secreted 
in keratinocyte-conditioned medium is biologically active and is 
likely the factor in conditioned medium largely responsible for 
stimulating HDMEC DNA synthesis. 
Detection of Two High-Affinity VPF/VEGF Binding Sites 
on HDMEC The binding of .125I-rhVPF/VEGF to HDMEC was 
satu.rable , specific, and of high affinity (Fig 7) . Saturation occurred 
at approximately 9-10 ng/ml with half maximal binding at approx-
imately 1-2 ng/ml. Scatchard analysis (Fig 7, iuse11) indicated that 
the data were best fit by two distinct high-affinity receptors having 
dissociation constants of 51 pM (27,000 sites/cell) and 2.9 pM 
(1,1 00 sites/ cell) . 
DISCUSSION 
VPF/VEGF potently induces microvascular hyperpermeability and 
angiogenesis iu vi11o [7 ,11-13,33-35). We have previously shown 
that VPF/VEGF mRNA is overexpressed in the epidermis of 
psoriatic skin lesions and ofhealing skin wounds [19,20], conditions 
that are characterized by angiogenesis and by increased microvas-
cular permeability. T hese results suggested that VPF/VEGF is a 
m<Uor, epidermis-derived angiogenesh factor in human skin. How-
ever, the mechanisms that regulate the expression ofVPF/VEGF in 
epidermal keratinocytes are poorly understood and VPF/VEGF's 
effect on dermal endothelial cells had not been investigated. 
Human epidermal keratinocytes, derived fi·om normal neonatal 
foreskins and cultured in serum-free complete KGM, secreted 
substantial amounts ofVPF/VEGF as detected by a specific Ruoro-
immunoassay. In contrast, keratinocytes in serum-free keratinocyte 
basal medium secreted substantially smaller amounts of VPF/ 
VEGF. T his difference was largely attributable to the presence of 
EGF as a supplement in KGM because EGF-enhanced keratinocyte 
secretion ofVPF/VEGF, in a dose-dependent fashion, when added 
to basal medium. TGF- a also enhanced keratinocyte VPF/VEGF 
secretion, a finding in accord with our earlier report (20]. Although 
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Figure 6. Mitogenic effect of keratinocyte-conditioned media on 
HDMEC DNA synthesis. Conditioned media were harvested from 
keratinocytes cultured for 48 h in serum-free KGM. Conditioned media or 
equivalent amounts ofKGM (control medium) were added to HDMEC for 
4 d. DNA synthesis is expressed as a stim ulatory index (mean ::': SD): ratio 
of thymidine incorporation by 1-!DMEC cultured with conditioned or with 
control medium (mean ::': SD; n = 4). 
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Figure 7. Specific and saturable binding o£ 1251-rhVPF/VEGF bind-
ing to HDMEC. Confluent l-IDMEC were incubated for 4 h at 4"C with 
1251-rhVl>F/VEGF (12 pg/ml to 9 ng/ml). The amount of bound and free 
1251-rhVPF/VEGF was determined as described in LVlnfcJinls n11d J\lfethods. 
Non-specific binding (S 22% of total binding) was determined in the 
presence of a one hundredfold excess of unlabeled rhVPF/VEGF. l11ser1, 
Scatchard plot. Binding data i11dicate the presence of two classes of high 
affirtity VPF/VEGF binding sites on HDMEC with dissociation constants of 
51 pM (27 ,000 sites/ cell) and 2. 9 pM (l,1 00 sites/ cell) . 
TGF-0' and EGF interact with the same receptor, the EGF receptor 
[36,37), TGF-a was more potent th an EGF at equivalent protein 
concentrations, and addition of gr·aded doses of EGF to medium 
containing 100 ng/ml TGF-a actually reduced the extent ofTGF-a 
stimulation (data not shown). These findings are compatible with 
previous reports demonstrating that TGF-a is more potent than 
EGF in several different assay systems; e.g., angiogenesis in the 
hamster cheek pouch [38], proliferation of human epithelial ceUs 
[39), and epidermal regeneration following partial thickness bum 
[40). Together these data support an important role for TGF-a ill 
the overexpression ofVPF/VEGF observed in healing wounds, in 
many epithelial tumors, and in psoriatic skin, all lesions that expres 
increased amounts of TGF-a, and the EGF receptor, but not 
necessarily EGF [ 41-43]. lt remains to be resolved whether other 
members of the EGF family are also involved in the regulation of 
VPF/VEGF expression in epidermal keratinocytes. 
To determine whether additional factors might contribute to the 
increased expression of VPF/VEGF by keratinocytes in psoriasis 
and healing wounds, we studied the effects of a number of other 
cytok.ines and growth factors that have been associated with both 
conditions. However, no significant VPF/VEGF induction was 
found after treatment of normal keratinocytes with II.-1, lL-6, lL-8, 
MCP-1, IFN-y, TN F-a, or TGF-,B . Several groups have reported 
that TGF-(3 upregulates the expression of VPF/VEGF in U937 
cells, smooth muscle cells, and human lung adenocarcinoma cells 
[44-46]; however, we found no significant alteration of VPF/ 
VEGF secretion by keratinocytes after 48 b incubation with TGF-~ 
in concentrations as high as 10 ng/ml. These data indicate that 
regulation of VPF/VEGF expression and secretion is likely to be 
under different control mechanisms in different cell types. More· 
over, additional stimuli very likely contribute to the enhanced 
VPF/VEGF expression in psoriasis and healing wounds. For exam• 
ple, recent data indicate that hypoxia induces increased expression 
of VPF/VEGF in the sk.in (M. Detmar cl nl, unpublished data). 
The VPF/VEGF f:unily is comprised of four different peptid~ 
isofonus as the result of alternative splicing of a single gene (16, 17], 
Whereas aU VPF/VEGF isofonns seem to have sinular biologi~ 
activities, only VPF/VEGF12 1 and VPF/VEGF1(,5 are secreted U\ 
soluble form, whereas the higher-molecular-weight forms appar, 
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ently remain cell associated [18]. T he results of our t;bonuclease 
protection assays indicate that mRNAs encoding the three most 
common isofonns, VPF/ VEGF121 , VPF/ VEGF165 , and, to a lesser 
extent, VPF/VEGF1 H9 , were all expressed by cultured keratino-
cytes. These results are in accordance with a recent report [47]. 
TGF-cx, EGF, and PMA strongly enhanced the e"--pression of all 
three isoforms. These data are of pathophysiologic significance in 
that we detected an identical pattern of altematively spliced 
VPF/VEGF mRNA expression in extracts obtained from the 
lesions of three patients with acute psoriasis, indicating an equiva-
lent expression ofVPF/VEGF isoforms in kerati.nocytes both in vivo 
and i11 vitro. 
To determine the biologic activity ofkeratinocyte-derived VPF/ 
VEGF on skin endothelial cells, we investigated the effect of 
kerati.nocyte-derived conditioned media that contained immunore-
active VPF/VEGF on the proliferation of HDMEC in 11itro. Kera-
tinocyte- conditioned m edia enhanced the DNA synthesis of cul-
tured HDMEC in a dose-dependent fashion, and depletion of 
VPF/VEGF by immunoadsorption markedly inhibited the mito-
genic effect of keratinocyte-conditioned m edia. Together these 
findings provided strong evidence that kerati.nocyte-derived VPF/ 
VEGF is mitogenic for dermal endothelial cells. Additional support-
ing evidence came from assays demonstrating a potent mitogenic 
effect ofrhVPF/ VEGF on HDMEC at concentrations of1.0 ng/ml 
or less (i. e ., at levels well within the range ofVPF/VEGF concen-
trations de tected in keratinocyte-conditioned media by immunoas-
say). The mitogenic effect of rhVPF/VEGF was selective for 
HDMEC because neither epidermal keratinocytes nor dennal 
fibroblasts were stimulated to proliferate in response to rh VPF/ 
VEGF. This feature distinguishes VPF/VEGF from other peptide 
growth factors such as basic fibroblast growth factor [48] and 
platele t-derived growth factor [ 49], which are less selective in their 
cellular targets. 
Finally, we detected high-affinity binding of 1 25 1-rhVPF/VEGF 
to HDMEC with saturation at 9 -10 ng/ml. Tlus value is in good 
agreement with our HDMEC proliferation data, which indicated a 
maxin~um mitogenic effect ofrhVPF/VEGF in concentrations of10 
ng/ml . Scatchard analysis indicated the presence of two classes of 
high-affinity VPF/VEGF binding sites with dissociation constants of 
51 pM (27,000 sites/cell) and 2.9 pM (1 ,100 sites/cell) . W e 
presume that the receptors w e have measured correspond to KDR 
[14] and ftt-1 [15] ; if so, they confirm our previous investigations of 
normal human skin, demonstrating relatively more abundant ex-
pression of KDR than ftt-1 mRNA i11 situ (M. Detmar et a/, 
unpublished data). However, the functional aspects of these recep-
tors as VPF/VEGF signal transducers remain tmclea.r. 
In conclusion, EGF and TGF-cx, as well as PMA, enhance the 
expression of VPF/VEGF mRNA in epidern~al kerati.nocytes and 
the secretion of biologically active VPF/ VEGF into the culture 
medium. VPF/VEGF is a selective mitogen for HDMEC, interact-
ing with two high-affmity receptors on the surface of dermal 
endothelial cells . Together with our previous findings of prominent 
VPF/VEGF overexpression in the epidermis of psoriatic lesions and 
healing wounds, the present findings suggest that VPF/VEGF is an 
important skin cytokine, released by the avascular epidermis in 
order to regulate local dern~al microvascular permeability and 
angiogenesis . Similar m echanisms may operate in a variety of 
inflammatory and neoplasti.c skin diseases that are characterized by 
microvascular hyperpermeability, papillary dermal edema, and an-
giogenesis. 
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